European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease : vimarsana.com

NEW YORK, March 13, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.

Related Keywords

Espa , Hordaland , Norway , Brazil , Australia , Canada , Liechtenstein , Spain , United States , Iceland , Italy , Lichtenstein , , European Union , Pfizer , Linkedin , European Commission , Exchange Commission , National Center , Drug Administration , Pfizer Inc , Youtube , Pneumococcal Conjugate Vaccine , Alexandre De Germay , Chief International Commercial Officer , Executive Vice President , European Medicines Agency , Medicinal Products , Human Use , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Bacterial Core , Lancet Infect , Hum Vaccin , Pediatric Infectious Disease , Published September ,